We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer Gets Complete Response Letter for Neuro Drug Vyndaqel
Pfizer Gets Complete Response Letter for Neuro Drug Vyndaqel
June 22, 2012
Pfizer has received a complete response letter from the FDA on its neuro drug Vyndaqel (tafamidis) after a negative advisory panel meeting, with agency staff and advisers raising concerns about the drug’s efficacy.